focus -WSS

focus

author：fashion 2025-09-27 17:03:22 - browse：9431

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Prime Medicine says its gene editing passes test in monkeys

knowledge

WSS

Elisabeth Bik tackles the widespread issue of research misconduct

Humans aren't the only ones with an imagination. Rats have it too

Pfizer is about to make a big push in cancer. Will investors listen?

Medicare Advantage isn’t working — for anyone

How neuroscience research could help beat back brain cancer

'Vaccine

Wikipedia

focus

entertainment

23andMe had bad news about my health. I wish a person had delivered it

Doctor of U.S. President Joe Biden says he is fit for duty

Psychedelics group wrestles with new pharma identity

Travis Kelce and the trap of celebrity vaccine endorsements

The cancer drug shortage isn’t new — and neither are the solutions

Infant mortality in U.S. rose last year for first time in decades: CDC

Virginia high school admissions case could be legal follow

Brain injuries and the importance of a second opinion

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sarepta Duchenne therapy fails to meet primary endpoint in trial

knowledge

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Color Health wants to make cancer screenings convenient

CDC advisory group OKs chikungunya vaccine

Ohio train derailment: Experts on toxic chemical risks

Explaining an after

Medicare isn't yet testing food as medicine

entertainment

leisure time

knowledge

knowledge